- Home
- BPOPM vs VCEL Comparison
BPOPM vs VCEL Comparison
Compare BPOPM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BPOPM
Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Current Price
Company Overview
Basic Information| Metric | BPOPM | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | BPOPM | VCEL |
|---|---|---|
| Price | $25.29 | $29.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.50 |
| AVG Volume (30 Days) | 1.1K | ★ 610.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ N/A | $96.31 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $24.54 | $29.24 |
| 52 Week High | $25.98 | $45.97 |
Technical Indicators
Market Signals| Indicator | BPOPM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 30.35 |
| Support Level | $25.25 | N/A |
| Resistance Level | $25.40 | $38.48 |
| Average True Range (ATR) | 0.02 | 1.52 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 30.00 | 9.09 |
Price Performance
Historical ComparisonAbout BPOPM Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Popular Capital Trust II is a statutory trust. It is engaged in issuing capital securities.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.